Thrombospondin-based antiangiogenic therapy
- 8 May 2007
- journal article
- review article
- Published by Elsevier in Microvascular Research
- Vol. 74 (2-3) , 90-99
- https://doi.org/10.1016/j.mvr.2007.04.007
Abstract
No abstract availableKeywords
This publication has 88 references indexed in Scilit:
- Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1)Journal of Cellular Physiology, 2006
- Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanesGenes & Development, 2006
- Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer modelCancer Letters, 2006
- Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combinationEuropean Journal Of Cancer, 2006
- Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic StrategyClinical Cancer Research, 2005
- Identification of CD36 molecular features required for its in vitro angiostatic activityThe FASEB Journal, 2005
- Thrombospondin-1 Mimetic Peptide Inhibitors of Angiogenesis and Tumor Growth: Design, Synthesis, and Optimization of Pharmacokinetics and Biological ActivitiesJournal of Medicinal Chemistry, 2005
- Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2Blood, 2003
- RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesisCancer Cell, 2003
- The Hallmarks of CancerCell, 2000